This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Spectrum Pharmaceuticals Highlights Promising ZEVALIN®, FOLOTYN® And Belinostat Clinical Data Presented At The 54th Annual Meeting Of The American Society Of Hematology

Abstract # 2742 - RIT with 90Y Ibritumomab Tiuxetan in Patients with Non-Hodgkin Lymphoma Over 65 Years

An investigator-sponsored Phase 2 study in patients over 65 years of age, mean age 72.8 years (range 65-87), with CD20+ NHL reported positive results, demonstrating that consolidation therapy with ZEVALIN early in the course of treatment resulted in a mean progression free survival (PFS) of 54.2 months . According to the authors of the clinical trial abstract, ZEVALIN “offers good and maintained response rate with lower toxicity in this fragile population.” Further, overall survival (OS) in this population was found to be not inferior to rates that have been observed in younger NHL patients.

Abstract # 3657 - Short Course of Bendamustine and Rituximab Followed by 90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naïve Follicular Lymphoma: Early Results of "Fol-Brite"

Results of an investigator-sponsored Phase 2 study in patients with grade 1-2 or 3a fNHL showed that of the patients who completed bendamustine and rituximab conditioning followed by consolidation treatment with ZEVALIN by the time of a pre-planned interim analysis, 85.7% had achieved a complete response (CR) rate. This CR rate, being announced for the first time in a major medical conference, well surpassed the level required to continue the study of this sequential therapeutic regimen, which the abstract authors noted was “a promising option for the treatment of follicular lymphoma.”

Abstract # 3681 - Sustained Immune Competency and Long Term Molecular Remissions in FL Patients with FLIPI Risk Factors >1, Treated Front Line with R-CHOP Followed by Consolidative 90 Υ-Radioimmunotherapy and Maintenance Rituximab

Clinicians at Sunnybrook Health Sciences Centre, Toronto, presented updated findings from a Phase 2 study in patients with high-risk (FLIPI 2-5), advanced-stage fNHL who received “triple therapy” of R-CHOP induction chemotherapy, followed by ZEVALIN consolidation and 2 years rituximab maintenance. Of those patients with PCR detectable t(14;18) translocations who were evaluated before and after Zevalin, 94% became PCR negative in blood following ZEVALIN consolidation, indicating Complete Response at the molecular level. For patients with FLIPI=2, 93% remained progression free over a median follow-up period of 32 months, a rate similar to or more favorable than previous reports.

3 of 8

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,113.54 +61.81 0.36%
S&P 500 1,983.53 +9.90 0.50%
NASDAQ 4,456.0160 +31.3120 0.71%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs